Blue Flower

Jose Saro, MD (Chair of SAB)

Dr. Saro has over 25 years of experience in the preclinical, translational and clinical development of oncology compounds.
Throughout his career, he has developed an extensive global network among oncologic academic institutions and the pharmaceutical industry.

Dr. Saro currently works at AstraZeneca where he leads the ceralasertib post-PARP inhibitor early clinical development program in solid tumors. Prior to that, he worked at Avacta as Chief Medical Officer driving the development strategy of Affimer® programs into the clinic. Before Avacta, Dr. Saro served as Senior Translational Medicine Leader at Roche where he ran three global immunotherapy programs – a targeted cytokine, and two T-cell bispecific antibodies in solid tumors – in collaboration with top academic institutions in the EU and US. Previously, he led global clinical programs at Bristol Myers Squibb including dasatinib, ipilimumab (anti-CTLA4), nivolumab (anti-PD1), anti-PDL1, anti-KIR, anti-LAG3, brivanib, a MEK inhibitor, and elotuzumab. While at Novartis he focused on biomarkers in the preclinical and clinical settings. Dr. Saro earned a medical degree from the University of Oviedo, Spain and a master’s degree in pharmaceutical medicine from Complutense University of Madrid, Spain.

Chiorean, E. Gabriela, MD

Professor of Medicine at University of Washington School of Medicine
Professor, Clinical Research Division at Fred Hutchinson Cancer Research Center
Director, Gastrointestinal Oncology Program at UW/Seattle Cancer Care Alliance
Clinical Research Director, Gastrointestinal Oncology at the UW Medicine/Fred Hutchinson Cancer Research Center

As a professor of medicine at the UW School of Medicine, professor at the Fred Hutchinson Cancer Research Center and attending physician at Seattle Cancer Care Alliance, Dr. Gabriela Chiorean strives to improve the care for patients with pancreatic and other gastrointestinal cancers. She leads early-stage as well as Phase 2 and 3 clinical trials of new therapies for these cancers, including new chemotherapies, immunotherapies and targeted drugs. She also aims to identify biomarkers of cancer, such as molecules in the blood, that could be developed into a minimally invasive test for the early detection of cancers or precancers. Dr. Chiorean works with collaborative groups of clinicians and researchers to implement cutting-edge clinical trials for pancreatic cancer patients. She chairs the Pancreatic Cancer Sub-Committee for the SWOG Cancer Research Network, is vice chair of the NCI Pancreatic Cancer Task Force, and chair of the Pancreatic Cancer Research Team.

O’Reilly, Eileen M., MD

Winthrop Rockefeller Endowed Chair in Medical Oncology
Section Head, Hepatopancreaticobiliary & Neuroendocrine Cancers
Co-Director Medical Initiatives, David M. Rubenstein Center for Pancreatic Cancer
Attending Physician, Member, Memorial Sloan Kettering Cancer Center
Professor of Medicine, Weill Cornell Medical College

Dr. O’Reilly is a medical oncologist whose research and clinical activities focus on treating pancreatic and hepatobiliary cancers. Her research initiatives include integrating molecular and genetic-based therapies into the treatment of pancreatic cancer, developing adjuvant and neoadjuvant therapies, and identifying biomarkers that may be used to select therapy. She is the principal investigator of multiple Phase 1, 2 and 3 pancreatic cancer clinical trials and has authored and co-authored more than 300 articles, editorials and book chapters.

Prof. Dr. Seufferlein, Thomas T. W.

Professor of Gastroenterology at the University of Ulm
Vice Dean for Research at the Medical Faculty of the University of Ulm
Chair of the Committee for Cancer Prevention of the German Cancer Aid
President of the German Cancer Society (Deutschen Krebsgesellschaft, DKG)
Spokesperson of the German Cancer Aid and the Association of the Scientific Medical Societies in Germany (Arbeitsgemeinschaft der Wissenschaftlichen Medizinischen Fachgesellschaften, AWMF)
Editor in Chief of the German Journal of Gastroenterology
General Secretary of the European Society for Digestive Oncology (ESDO)

Prof. Seufferlein has a particular interest in gastrointestinal (GI) oncology and the molecular basis of GI cancers, in particular pancreatic cancer, and pioneering the clinical use of novel treatments. He has been an active member of working and leading groups of the DKG and a spokesperson of the Certification Commission of Visceral Oncology Centers of the DKG for several years. His clinical and basic research interests include compartment specific signaling in cancer, regulation of cellular protein transport, tumor-host-interaction and the organization of the tumor cell cytoskeleton and biomarkers. Prof. Seufferlein was involved in setting up the German National Guidelines and the European Society for Medical Oncology (ESMO) guidelines for the diagnosis and treatment of pancreatic cancer. He has authored and co-authored more than 300 scientific articles, reviews and opinions.

Von Hoff, Daniel D., MD, FACP, FASCO, FAACR

Distinguished Professor and Executive Vice President, Molecular Medicine
Translational Genomics Research Institute (TGEN)
Virginia G. Piper Distinguished Chair for Innovative Cancer Research
and Chief Scientific Officer, Honor Health Research Institute
Chair of the Early Drug Development Committee, US Oncology
Distinguished Professor, Department of Medical Oncology and Therapeutic Research, City of Hope
Professor of Medicine, Mayo Clinic

Dr. Von Hoff’s major interest is in the development of new anticancer agents, both in the clinic and in the laboratory. He and his colleagues were involved in the beginning of the development of many FDA approved agents we now use routinely, including: mitoxantrone, fludarabine, paclitaxel, docetaxel, gemcitabine, irinotecan, nelarabine, capecitabine, lapatinib, vismodegib, nab-paclitaxel, nal-IRI, pexidartinib and others. His clinical trial work has led to the approval of three of the four drugs approved by the FDA for treatment of patients with advanced pancreatic cancer. At present, he and his colleagues are concentrating on the development of therapies for patients with advanced pancreatic cancer.